| Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders LJ Brown, A Weppler, P Bhave, C Allayous, JR Patrinely Jr, P Ott, ... Journal for immunotherapy of cancer 9 (5), 2021 | 43 | 2021 |
| Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer A Freelander, LJ Brown, A Parker, D Segara, N Portman, B Lau, E Lim Genes 12 (2), 285, 2021 | 28 | 2021 |
| Epigenetic Therapies and Biomarkers in Breast Cancer LJ Brown, J Achinger-Kawecka, N Portman, S Clark, C Stirzaker, E Lim Cancers 14 (3), 474, 2022 | 24 | 2022 |
| The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis JM Versluis, AM Hendriks, AM Weppler, LJ Brown, K de Joode, ... European Journal of Cancer 151, 72-83, 2021 | 16 | 2021 |
| PARP Inhibitors in Melanoma—An Expanding Therapeutic Option? WY Chan, LJ Brown, L Reid, AM Joshua Cancers 13 (18), 4520, 2021 | 14 | 2021 |
| 64Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety … K Wong, G Sheehan-Dare, A Nguyen, B Ho, V Liu, J Lee, L Brown, ... Pharmaceuticals 15 (7), 772, 2022 | 11 | 2022 |
| Heart Failure Therapies for the Prevention of HER2-Monoclonal Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Trials LJ Brown, T Meredith, J Yu, A Patel, B Neal, C Arnott, E Lim Cancers 13 (21), 5527, 2021 | 7 | 2021 |
| The nature and management of acquired resistance to PD1-based therapy in melanoma. A Hepner, JM Versluis, CL Gerard, LJ Brown, R Wallace, P Bhave, ... Journal of Clinical Oncology 38 (15_suppl), 10014-10014, 2020 | 6 | 2020 |
| Five‐year survival and clinical correlates among patients with advanced non‐small cell lung cancer, melanoma and renal cell carcinoma treated with immune check‐point inhibitors … LJ Brown, IP da Silva, T Moujaber, B Gao, R Hui, H Gurney, M Carlino, ... Cancer Medicine 12 (6), 6788-6801, 2023 | 5 | 2023 |
| An unusual presentation of varicella zoster virus with acute cerebellitis and SIADH without a rash M Lubomski, L Brown, R Markus Journal of Clinical Neuroscience 41, 90-91, 2017 | 5 | 2017 |
| Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD). LJ Brown, A Weppler, P Bhave, C Allayous, JR Patrinely, PA Ott, ... Journal of Clinical Oncology 38 (15_suppl), 10026-10026, 2020 | 4 | 2020 |
| Activity and safety of third-line BRAF-targeted therapy (TT) following first-line TT and second-line immunotherapy (IT) in advanced melanoma. V Atkinson, K Batty, GV Long, MS Carlino, GD Peters, P Bhave, MA Moore, ... Journal of Clinical Oncology 38 (15_suppl), 10049-10049, 2020 | 3 | 2020 |
| 1080MO The value of local therapy in treatment of solitary melanoma progression upon immune checkpoint inhibition JM Versluis, AM Hendriks, A Weppler, L Brown, K de Joode, ... Annals of Oncology 31, S733-S734, 2020 | 2 | 2020 |
| The features and management of acquired resistance to PD1-based therapy in metastatic melanoma A Hepner, JM Versluis, R Wallace, C Allayous, LJ Brown, C Trojaniello, ... European Journal of Cancer 196, 113441, 2024 | 1 | 2024 |
| 64Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2- metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial. K Wong, G Sheehan-Dare, A Nguyen, B Ho, V Liu, J Lee, LJ Brown, ... Journal of Clinical Oncology 40 (16_suppl), 3092-3092, 2022 | 1 | 2022 |
| Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer—Real World Outcomes After Two Years of Therapy (COPILOT) A Fantoni, L Warburton, B Solomon, M Alexander, M Maddula, LJ Brown, ... Clinical Lung Cancer, 2024 | | 2024 |
| The influence of transcatheter aortic valve replacement on left atrial mechanics: a systematic review and meta-analysis T Meredith, L Brown, F Mohammed, A Pomeroy, D Roy, DWM Muller, ... European Heart Journal-Imaging Methods and Practice 2 (2), qyae026, 2024 | | 2024 |
| 202P Clinical outcomes to second-line treatment, after failing chemoimmunotherapy, in ES-SCLC VJ Andreas, M Faltys, M Alexander, J Rogers, S Parakh, SE Bowyer, ... ESMO Open 9, 2024 | | 2024 |
| First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study LJ Brown, V Khou, C Brown, M Alexander, D Jayamanne, J Wei, L Gray, ... Frontiers in Oncology 14, 1305720, 2024 | | 2024 |
| Clinical outcomes to second-line treatment, after failing chemoimmunotherapy, in ES-SCLC VJ Andreas, M Faltys, M Alexander, J Rogers, S Parakh, SE Bowyer, ... | | 2024 |
